a year ago

PlaqueTec Secures £6.4 Million to Advance Precision Medicine for Coronary Artery Disease

  • PlaqueTec, a UK-based company developing biomarkers for precision medicine in coronary artery disease (CAD), raised £6.4 million in funding

  • The round was led by Lord Moynihan of Chelsea with support from the Future Fund and existing investors

  • PlaqueTec plans to use the funds to support its ongoing Biopattern trial, designed to improve understanding of CAD pathobiology and build Biocarta, a novel biomarker discovery tool

  • The company has developed a proprietary technology and data analysis platform to endotype patients and uncover potential biomarkers of coronary vascular function and plaque progression

  • Their Biocarta platform interrogates data and groups patients with CAD into endotypes with defined signatures of the disease

  • The company is using Biocarta to identify biomarkers for more targeted therapeutic interventions, transforming patient care

      • ProblemHealthcare

      "Coronary artery disease (CAD) is a leading cause of death globally. It's caused by a build-up of plaque in the arteries, which narrows or blocks the blood supply to the heart. Current treatments are often ineffective because they don't address the individual variations in how the disease progresses."

      Solution

      "PlaqueTec is developing a novel biomarker discovery tool called BIOCARTA. BIOCARTA uses a bioinformatics platform to analyse data and group patients with CAD into 'endotypes' with unique disease signatures. This allows them to identify biomarkers that can accurately assess patients and inform more targeted therapeutic interventions, transforming patient care."

      Covered on